Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT)
Trade-Ideas LLC identified
(
) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Sarepta Therapeutics as such a stock due to the following factors:
- SRPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $63.9 million.
- SRPT has traded 164,378 shares today.
- SRPT is up 6.6% today.
- SRPT was down 8.7% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in SRPT with the Ticky from Trade-Ideas. See the FREE profile for SRPT NOW at Trade-Ideas
More details on SRPT:
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Currently there are 3 analysts that rate Sarepta Therapeutics a buy, 5 analysts rate it a sell, and 5 rate it a hold.
The average volume for Sarepta Therapeutics has been 5.7 million shares per day over the past 30 days. Sarepta has a market cap of $805.6 million and is part of the health care sector and drugs industry. The stock has a beta of 1.33 and a short float of 46.8% with 5.78 days to cover. Shares are down 50.4% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Sarepta Therapeutics as a
. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and poor profit margins.
Highlights from the ratings report include:
- The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
- Net operating cash flow has decreased to -$60.69 million or 40.00% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The gross profit margin for SAREPTA THERAPEUTICS INC is currently extremely low, coming in at 0.00%. SRPT has continued with the weak profit margin when compared to the same quarter of last year.
- SAREPTA THERAPEUTICS INC has improved earnings per share by 12.1% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, SAREPTA THERAPEUTICS INC reported poor results of -$5.19 versus -$3.39 in the prior year. This year, the market expects an improvement in earnings (-$4.27 versus -$5.19).
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500, but is less than that of the Biotechnology industry average. The net income increased by 2.9% when compared to the same quarter one year prior, going from -$61.56 million to -$59.77 million.
- You can view the full Sarepta Therapeutics Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
